AC BioScience, a fledgling biotechnology firm with a pioneering vision and unique business approach, is deeply committed to pioneering innovative therapies to combat various forms of cancer. Two of the company's primary oncology compounds are set to progress to the clinical phase in 2021/2022. Co-founded by Andreas Schläpfer and Professor Christian Auclair, the organization is spearheading a revolutionary change in cancer treatment. Situated at the Biopôle life sciences campus near Lausanne, AC BioScience celebrated its third anniversary in March 2020.
Ac Bioscience
Headquarters
France